Biocon Biologics announced it has signed a Distribution Agreement with Sandoz granting Sandoz the exclusive right to promote, sell and distribute “adalimumab BS for subcutaneous injection”, a biosimilar to Amgen’s Humira®, in Japan.
Biocon Biologics acquired the global biosimilars portfolio of Viatris with a deal signed in November 2022. It completed integration in Europe in November 2023, and in North America in September 2023. The most recent announcement states that Viatris will continue to provide transition support until Sandoz assumes responsibility for the product from 15 February 2024.